Dr. Rongsheng (Ross) Wang
Assistant Professor Email: [email protected] Office: SERC 642 Phone: 215-204-1855 Academic Career- Academic Tree Postdoctoral Fellow 2012-2016. The Scripps Research Institute. Advisor: Peter G. Schultz Ph.D. Chemistry 2010. Washington University in St Louis. Advisor: John-Stephen Taylor B.S. Chemistry 2005. Nanjing University Advisor: Zijian Guo Industrial Experience Research Scientist 2010-2012. Mediomics, LLC |
Biography
- American Chemical Society Medicinal Chemistry (MEDI) Young Investigator (2023)
- Rising Star - International Chemical Biology Society Young Chemical Biologist Award (2022)
- OVPR Catalytic Collaborative Initiative (CAT) Award (2022)
- Cottrell Scholar (2021)
- NSF CAREER Award (2021)
- Temple University CST, Distinguished Teaching Award (2021)
- Chemical Machinery of the Cell Collaborative Innovation Award (2019, 2021)
- Research Cooperation Scialog Fellow (2019)
- NIH Maximizing Investigators' Research Award - R35 (2019)
- The Joe Moakley Leukemia SPORE Career Enhancement Award, University of Texas, MD Anderson (2019)
- American Cancer Society IRG Award (2017)
- Fox Chase Cancer Center CCSG Pilot Research Award (2017)
- Temple University, Summer Research Award (2017)
- California Institute for Biomedical Research-STIP Award (2015)
- Elsevier Excellent Reviewer (2013)
Ross obtained his undergraduate degree in bioinorganic chemistry from Nanjing University (NJU), China, between 2001 and 2005. From 2005, Ross joined the Ph.D. program in bioorganic chemistry at Washington University in St Louis (WUSTL). His thesis work with Prof. John-Stephen Taylor focused on the development and study of small molecule/peptide-based inhibitors and probes of heat shock protein 70. From 2010 to 2012, Ross spent a short spell at a local biotech company, Mediomics, LLC, to invent protein or aptamer -based fluorescence sensors that enable homogeneous rapid detection of biomarkers. In 2012, Ross joined the laboratory of Prof. Peter G. Schultz as a postdoctoral research fellow at the Scripps Research Institute (TSRI). In the postdoctoral work period, Ross was engaged in inventing a new generation of site-specific antibody drug conjugates for treating inflammatory disorders. He was also actively involved in the discovering of a protein engineering platform that can generate functional antibodies to serve as the first-in-class selective therapeutics for cancer and autoimmune diseases. From July 2016, Ross started his independent research career at Temple University, Department of Chemistry, and was also appointed as the primary member of the molecular therapeutics program at Fox Chase Cancer Center. The focus of his current research is the invention of bioorthogonal chemical reactions and the development of various chemical biological tools, which allow us to interrogate complex biological systems and to develop novel therapeutics.